[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1247629A1 - 用於獲得肉毒桿菌神經毒素的方法和系統 - Google Patents

用於獲得肉毒桿菌神經毒素的方法和系統

Info

Publication number
HK1247629A1
HK1247629A1 HK18107202.9A HK18107202A HK1247629A1 HK 1247629 A1 HK1247629 A1 HK 1247629A1 HK 18107202 A HK18107202 A HK 18107202A HK 1247629 A1 HK1247629 A1 HK 1247629A1
Authority
HK
Hong Kong
Prior art keywords
botulinum neurotoxin
obtaining botulinum
obtaining
neurotoxin
botulinum
Prior art date
Application number
HK18107202.9A
Other languages
English (en)
Inventor
Jennifer L Ton
Hemant A Patel
Ronald C Bates
Wajdie M Ahmad
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1247629(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1247629A1 publication Critical patent/HK1247629A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18107202.9A 2009-07-13 2018-06-01 用於獲得肉毒桿菌神經毒素的方法和系統 HK1247629A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
HK1247629A1 true HK1247629A1 (zh) 2018-09-28

Family

ID=42537891

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107202.9A HK1247629A1 (zh) 2009-07-13 2018-06-01 用於獲得肉毒桿菌神經毒素的方法和系統

Country Status (19)

Country Link
US (19) US8129139B2 (zh)
EP (5) EP4299070A3 (zh)
JP (6) JP5887268B2 (zh)
KR (5) KR101916139B1 (zh)
CN (2) CN106117325B (zh)
BR (1) BR112012000784A2 (zh)
CA (1) CA2767760C (zh)
CY (2) CY1119519T1 (zh)
DK (2) DK3252070T3 (zh)
ES (2) ES2770031T3 (zh)
HK (1) HK1247629A1 (zh)
HU (2) HUE047362T2 (zh)
IN (1) IN2012DN00456A (zh)
MX (3) MX340718B (zh)
PL (2) PL3252070T3 (zh)
PT (2) PT2454275T (zh)
RU (1) RU2561459C2 (zh)
SI (2) SI2454275T1 (zh)
WO (1) WO2011008713A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
JP4913074B2 (ja) 2005-03-03 2012-04-11 アラーガン、インコーポレイテッド 動物由来産物不含方法およびボツリヌス毒素を精製するための方法
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120196349A1 (en) 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
KR20110046178A (ko) * 2009-10-28 2011-05-04 엘지전자 주식회사 이동 단말기
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
RU2663136C2 (ru) * 2013-07-30 2018-08-01 Мерц Фарма Гмбх Унд Ко. Кгаа Способ получения высокочистого нейротоксического компонента ботулотоксина и его применения
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US20160287693A1 (en) * 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
US20210108187A1 (en) * 2017-04-28 2021-04-15 Bonti, Inc. Botulinum neurotoxins production methods
EP3644971A4 (en) * 2017-06-26 2021-03-31 Bonti, Inc. CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
US11926853B2 (en) 2018-12-21 2024-03-12 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102209159B1 (ko) * 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
BR112022009932A2 (pt) * 2019-12-20 2022-08-09 Galderma Holding SA Método de produção de toxina botulínica.
TW202136286A (zh) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
WO2023282653A1 (ko) * 2021-07-08 2023-01-12 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
KR20240015446A (ko) * 2022-07-27 2024-02-05 (주)이니바이오 감압건조장치 및 이를 이용한 감압건조방법
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) * 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
TW257792B (zh) * 1992-10-01 1995-09-21 Lilly Co Eli
NZ257215A (en) 1992-10-13 1996-12-20 Univ Duke Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
ATE239491T1 (de) 1995-06-06 2003-05-15 L Bruce Pearce Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
AU7545298A (en) 1997-05-28 1998-12-30 Chiron S.P.A. Culture medium with yeast or soy bean extract as aminoacid source and no proteincomplexes of animal origin
JP4055248B2 (ja) 1998-05-25 2008-03-05 味の素株式会社 精製ヒトアクチビン及びその製造方法
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001036655A2 (en) 1999-11-12 2001-05-25 Eli Lilly And Company Method for optimization of a medium for glycopeptide fermentation
WO2001036635A2 (en) 1999-11-15 2001-05-25 Curagen Corporation Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
DE10004024A1 (de) 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
NZ530779A (en) 2000-02-08 2004-08-27 Allergan Inc Botulinum toxin pharmaceutical compositions with recombinant albumin and device for injecting
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
AU2001272058A1 (en) 2000-02-10 2001-08-20 Magna Intertional Inc. Vehicle tailgate with storage capacity
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
DE60226327T2 (de) 2001-08-14 2009-07-09 Statens Serum Institut Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
KR20030060150A (ko) 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
CA2472611C (en) * 2003-07-02 2009-09-15 Filtertek Inc. Multiple retainer bridge
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
WO2005072433A2 (en) 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
CA2558758C (en) 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US20070277577A1 (en) * 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
CN101098883B (zh) 2004-12-23 2013-01-23 诺和诺德医疗保健公司 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量
JP4913074B2 (ja) 2005-03-03 2012-04-11 アラーガン、インコーポレイテッド 動物由来産物不含方法およびボツリヌス毒素を精製するための方法
ATE470857T1 (de) 2005-04-05 2010-06-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
KR101423272B1 (ko) 2005-11-17 2014-07-30 레반스 테라퓨틱스, 아이엔씨. 감소된 비-독소 단백질을 갖는 보툴리눔 독소의 국소 적용및 경피 전달을 위한 조성물 및 방법
SG2014009112A (en) 2008-03-14 2014-04-28 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
CA2753894C (en) 2009-03-13 2017-12-05 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120196349A1 (en) 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing

Also Published As

Publication number Publication date
KR20170019489A (ko) 2017-02-21
KR20180122039A (ko) 2018-11-09
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
US20220204958A1 (en) 2022-06-30
JP2024111147A (ja) 2024-08-16
US20160097045A1 (en) 2016-04-07
US11525130B2 (en) 2022-12-13
US9206409B2 (en) 2015-12-08
US20120156756A1 (en) 2012-06-21
JP6704329B2 (ja) 2020-06-03
EP4299070A3 (en) 2024-03-27
US20220145279A1 (en) 2022-05-12
KR101784532B1 (ko) 2017-10-11
JP2020078306A (ja) 2020-05-28
US20120123095A1 (en) 2012-05-17
US11518986B2 (en) 2022-12-06
KR20190111161A (ko) 2019-10-01
US11124786B2 (en) 2021-09-21
DK2454275T3 (en) 2017-10-23
KR101667174B1 (ko) 2016-10-17
US20120108792A1 (en) 2012-05-03
RU2012104778A (ru) 2013-08-20
HUE033888T2 (en) 2018-01-29
US8324349B2 (en) 2012-12-04
US8932827B2 (en) 2015-01-13
EP2454275B1 (en) 2017-07-12
IN2012DN00456A (zh) 2015-05-15
US11326155B2 (en) 2022-05-10
JP5887268B2 (ja) 2016-03-16
BR112012000784A2 (pt) 2020-08-11
US8129139B2 (en) 2012-03-06
PL3252070T3 (pl) 2020-04-30
CY1122567T1 (el) 2021-01-27
KR102344985B1 (ko) 2021-12-31
EP3252070A1 (en) 2017-12-06
MX2012000615A (es) 2012-03-26
US11530400B2 (en) 2022-12-20
KR20150085140A (ko) 2015-07-22
CA2767760A1 (en) 2011-01-20
US20230123158A1 (en) 2023-04-20
US20220298496A1 (en) 2022-09-22
ES2770031T3 (es) 2020-06-30
US20210292727A1 (en) 2021-09-23
EP4141024A1 (en) 2023-03-01
KR20120105417A (ko) 2012-09-25
SI2454275T1 (sl) 2017-12-29
CN102482332B (zh) 2016-08-03
CN106117325A (zh) 2016-11-16
EP3640259A1 (en) 2020-04-22
US20230029327A1 (en) 2023-01-26
PT3252070T (pt) 2020-01-14
US20200071686A1 (en) 2020-03-05
JP2021193103A (ja) 2021-12-23
US20230021648A1 (en) 2023-01-26
HUE047362T2 (hu) 2020-04-28
CY1119519T1 (el) 2018-03-07
US10465178B2 (en) 2019-11-05
US20120245324A1 (en) 2012-09-27
JP2012532932A (ja) 2012-12-20
US11203748B2 (en) 2021-12-21
MX2020009978A (es) 2020-10-12
US9719076B2 (en) 2017-08-01
PL2454275T3 (pl) 2017-12-29
US20220251532A1 (en) 2022-08-11
JP2017070291A (ja) 2017-04-13
EP2454275A1 (en) 2012-05-23
JP2016028601A (ja) 2016-03-03
MX340718B (es) 2016-07-22
US8927229B2 (en) 2015-01-06
DK3252070T3 (da) 2020-01-20
SI3252070T1 (sl) 2020-03-31
ES2643554T3 (es) 2017-11-23
US20220228136A1 (en) 2022-07-21
PT2454275T (pt) 2017-10-23
KR101916139B1 (ko) 2018-11-08
US8357541B2 (en) 2013-01-22
CN106117325B (zh) 2021-08-10
EP4299070A2 (en) 2024-01-03
RU2561459C2 (ru) 2015-08-27
EP3252070B1 (en) 2019-10-02
US20150184141A1 (en) 2015-07-02
WO2011008713A1 (en) 2011-01-20
US20170327811A1 (en) 2017-11-16
CN102482332A (zh) 2012-05-30
JP6356651B2 (ja) 2018-07-11
US20220033796A1 (en) 2022-02-03
US20110008843A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
HK1247629A1 (zh) 用於獲得肉毒桿菌神經毒素的方法和系統
HRP20181869T1 (hr) Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
EP2419128A4 (en) MANIPULATED BOTULINUM NEUROTOXIN
EP2497193A4 (en) SYSTEM AND METHOD FOR MOBILE INTERACTION
IL244154A0 (en) Botulinum neurotoxin for use in the treatment of depression
TWI365145B (en) Method and system for asisting driver
EP2481217A4 (en) SYSTEM AND METHOD FOR MICROCLOUD COMPUTING
EP2460354A4 (en) SYSTEM AND METHOD FOR IMPROVING VIDEO QUALITY
HK1148155A1 (en) Method and system for processing signal
EP2395130A4 (en) METHOD AND SYSTEM FOR FACTORY OPERATION
EP2462569A4 (en) METHOD AND SYSTEM FOR PARALLEL ACCOUNTING PROCESSING
GB0921076D0 (en) Handover system and method thereof
GB0800927D0 (en) Botulinum neurotoxin vaccine
EP2500858A4 (en) CONSTRUCTION PROCESS CREATION SYSTEM AND METHOD FOR CREATING CONSTRUCTION PROCESS
IL214372A0 (en) Means and methods for manufacturing highly pure neurotoxin
EP2517088A4 (en) SYSTEM AND METHOD FOR MULTIMODE CONTROL INPUT
EP2443602A4 (en) MARKETING SYSTEM AND METHOD
EP2507618A4 (en) METHOD AND SYSTEM FOR INTERACTION ANALYSIS
GB0903274D0 (en) Fluoreence method and system
IL218455A0 (en) System for determining unprocessed and partially processed neurotoxin type a
TWI365113B (en) System and method for laser processing
PL2416889T3 (pl) System i sposób szklenia
GB201504199D0 (en) Method and system
ZA201201689B (en) System for determining unprocessed and partially processes neurotoxin type a
ZA201200145B (en) System and method for marketing